Monocarboxylate transporters as targets and mediators in cancer therapy response.
Open accessThe DOI matches its OpenAlex record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Monocarboxylate transporters (MCTs) belong to a family of transporters, encoded by the SLC16 gene family, which is presently composed by 14 members, but only MCT1 to 4 have been biochemically characterized. They have important functions in healthy tissues, being involved in the transmembrane transport of lactic acid and other monocarboxylic acids in human cells. One of the recently recognized hallmarks of cancer is altered metabolism, with high rates of glucose consumption and consequent lactate production. To maintain this metabolic phenotype, cancer cells upregulate a series of plasma membrane proteins, including MCTs. MCT1 and MCT4, in particular, play a dual role in the maintenance of the metabolic phenotype of tumour cells. On one hand, they facilitate the efflux of lactate and, on the other hand, they contribute to the preservation of the intracellular pH, by co-transporting a proton. Thus, MCTs are attractive targets in cancer therapy, especially in cancers with a hyper-glycolytic and acid-resistant phenotype. Recent evidence demonstrates that MCTs are involved in cancer cell uptake of chemotherapeutic agents, including 3-bromopyruvate. In this way MCTs can act as "Trojan horses", as their elevated expression in cancer cells can mediate the entry of this chemotherapeutic agent into the cells and selectively kill cancer cells. As a result, MCTs will be mediators of chemotherapeutic response, and their expression can be used as a molecular marker to predict response to chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088 · cited 1×
“Although much less energetically efficient than oxidative phosphorylation, glycolysis provides several advantages to cancer cells, such as allowing survival under intermittent hypoxia (Gatenby and Gillies, 2004; Gillies and Gatenby, 2007), being a source of anabolic substrates essential for biosynthetic pathways (Gate…”
BackgroundTumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Pao, S. S., Paulsen, I. T., & Saier, M. H. (1998) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.62.1.1-34.1998 · Cited by 2,297 · cited 1×
“Monocarboxylate transporters (MCTs) belong to a family of transporters, encoded by the SLC16 gene family, which is presently composed by 14 members (Pao et al., 1998; Halestrap and Meredith, 2004).”
BackgroundThe reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma
Pavlides, S., Whitaker-Menezes, D., Castello-Cros, R., Flomenberg, N., Witkiewicz, A. K., Frank, P. G., Casimiro, M. C., Wang, C., Fortina, P., Addya, S., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10238 · Cited by 1,391
Végran, F., Boidot, R., Michiels, C., Sonveaux, P., & Feron, O. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2828 · Cited by 816 · cited 1×
“an important link between tumour metabolism and angiogenesis, mediated by the released lactate, which stimulates the NF-KB/IL-8 pathway (Vegran et al., 2011).”
BackgroundWolf, A., Agnihotri, S., Micallef, J., Mukherjee, J., Sabha, N., Cairns, R., Hawkins, C., & Guha, A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101470 · Cited by 789
Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter
Friesema, E. C. H., Ganguly, S., Abdalla, A., Fox, J. E. M., Halestrap, A. P., & Visser, T. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300909200 · Cited by 725
Role of monocarboxylate transporters in human cancers: state of the art
Pinheiro, C., Longatto-Filho, A., Azevedo-Silva, J., Casal, M., Schmitt, F. C., & Baltazar, F. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9428-1 · Cited by 368
Self-citationPRICE, T. N., JACKSON, N. V., & HALESTRAP, P. A. (1998) · Biochemical Journal · doi:10.1042/bj3290321 · Cited by 361 · cited 2×
“MCT1 has a ubiquitous distribution in human tissues, with an important expression in heart and muscle (Lin et al., 1998; Price et al., 1998; Fishbein et al., 2002).”
BackgroundEffective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10
Friesema, E. C. H., Jansen, J., Jachtenberg, J.-W., Visser, W. E., Kester, M. H. A., & Visser, T. J. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0112 · Cited by 285
Mathupala, S. P., Parajuli, P., & Sloan, A. E. (2004) · Neurosurgery · doi:10.1227/01.neu.0000143034.62913.59 · Cited by 147
Cited by
Nunes, A. S., Barros, A. S., Costa, E. C., Moreira, A. F., & Correia, I. J. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26845 · Cited by 721
Monocarboxylate transporters in the brain and in cancer
Pérez-Escuredo, J., Van Hée, V. F., Sboarina, M., Falces, J., Payen, V. L., Pellerin, L., & Sonveaux, P. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.013 · Cited by 402
Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement
Liu, J., Chen, Q., Feng, L., & Liu, Z. (2018) · Nano Today · doi:10.1016/j.nantod.2018.06.008 · Cited by 327
Lactic Acid: No Longer an Inert and End-Product of Glycolysis
Sun, S., Li, H., Chen, J., & Qian, Q. (2017) · Physiology · doi:10.1152/physiol.00016.2017 · Cited by 314
Zhang, L., Yao, Y., Zhang, S., Liu, Y., Guo, H., Ahmed, M., Bell, T., Zhang, H., Han, G., Lorence, E., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau1167 · Cited by 233
“SLC16A1 encodes a proton-coupled monocarboxylate transporter (also known as MCT-1), which is an essential transporter of lactate and pyruvate up-regulated in many solid tumors (23) and maintains the metabolic phenotype of tumor cells (24).”
Background
Metadata
- Authors
- Baltazar, F., Pinheiro, C. M., Morais-Santos, F., Azevedo‐Silva, J., Queirós, O., Preto, A., & Casal, M.
- Venue
- PubMed
- Publisher
- National Institutes of Health
- Published
- 2014-12-01
- Volume
- 29
- Issue
- 12
- Pages
- 1511-24
- OpenAlex
- W2124627517
- Cited by
- 112
- References
- 11
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.